CVRX · CIK 1235912
What CVRx, Inc. told the SEC could break it.
CVRx is essentially a one-product company: it derives nearly all revenue from Barostim, so its ability to grow and reach profitability depends entirely on continuing to commercialize that device and its enhancements. That single-product bet is tightened by its financing — term loans secured by substantially all of its personal property and carrying a covenant requiring it to hit 50% of its board-approved trailing-12-month revenue target, a meaningful constraint for an unprofitable company. Adoption is also reimbursement-dependent, with about 67% of its target population Medicare-eligible, so any cut to Medicare or third-party reimbursement for Barostim procedures would slow uptake and pressure pricing, and its European sales add foreign-currency exposure.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- secured term loans with revenue performance covenantmedium
CVRx's term loans are secured by substantially all of its personal property and carry a covenant requiring it to hit 50% of its board-approved trailing-12-month revenue target — a risk for an unprofitable company.
“The Term Loans are secured by substantially all of our personal property.”
SEC filing →As of 2026
Other disclosures
- single-product dependence (Barostim)medium
CVRx derives essentially all revenue from one product, Barostim; its ability to grow and reach profitability depends entirely on continued successful commercialization of Barostim and its enhancements.
“Our ability to generate significant revenue from product sales and become profitable will depend on our ability to continue to successfully commercialize Barostim and any product enhancements we may advance in the future.”
SEC filing →As of 2026
Currency (FX)
- foreign currency exposure on European saleslow
CVRx's European (Germany and select countries) Barostim sales are subject to foreign-currency exchange-rate fluctuations that can significantly impact international revenue.
“Our revenue from international sales can also be significantly impacted by fluctuations in foreign currency exchange rates.”
SEC filing →As of 2026
Regulatory & policy
- Medicare / third-party reimbursement for Barostim procedureslow
About 67% of CVRx's target population is Medicare-eligible; any decline in Medicare or third-party reimbursement for Barostim procedures would slow adoption and pressure pricing.
“Any future decline in the amount Medicare is willing to reimburse our customers for procedures using Barostim could make it difficult for new customers to adopt Barostim and could create additional pricing pressure for us, which could adversely affect our ability to invest in and grow our business, or establish Barostim as the standard of care.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch